FDA Drug · D-0471-2026

Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR

Class II · Ongoing

Lack of Assurance of Sterility

Affected lots / codes — check yours against thisLot Number 01-27-2026@14S.5

Recalling firm: PAYLESS COMPOUNDERS, LLC, Beaverton, OR
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 91 vials
Distribution: OR
Recall initiated: March 6, 2026
Classified: April 13, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0471-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →